<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>66</patient-age><report-id>US-NOVOPROD-369098</report-id><gender>male</gender><reactions><reaction>Branch retinal vein occlusion</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>Liraglutide FlexPen</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Type 2 diabetes mellitus</indication></indications><patient-age>66</patient-age><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170158_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-NOVOPROD-369098</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-16</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-16</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-NOVOPROD-369098</companynumb>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Faramarz</reportergivename>
			<reporterfamilyname>Ismail-Beigi</reporterfamilyname>
			<reporterorganization>Va Med Center</reporterorganization>
			<reporterstreet>10701 East Blvd 1B-129</reporterstreet>
			<reportercity>Cleveland</reportercity>
			<reporterstate>Ohio</reporterstate>
			<reporterpostcode>44106</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
			<studyname>Trial title:Liraglutide Effect and Action in Diabetes:Evaluation of cardiovascular outcome Results
</studyname>
			<sponsorstudynumb>EX2211-3748</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinvestigationnumb>PRIVACY</patientinvestigationnumb>
			<patientonsetage>66</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientweight>76.417</patientweight>
			<patientheight>166</patientheight>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1988</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Dyslipidaemia</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2004</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Gastrooesophageal reflux disease</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2008</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Retinopathy</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20040920</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Neuropathy peripheral</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2001</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal failure chronic</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2004</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Myocardial infarction</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Left ventricular hypertrophy</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pancreatitis</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2000</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>602</patientmedicalenddateformat>
				<patientmedicalenddate>2000</patientmedicalenddate>
				<patientmedicalcomment>Type? Acute</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tobacco user</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Branch retinal vein occlusion</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Venous tributary (branch) occlusion of retina</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Retinal vein occlusion</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120904</reactionstartdate>
				<reactionfirsttime>259</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>136</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Liraglutide FlexPen</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>22-341</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.0 mg, qd</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution for injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-12-20</drugstartdate>
				<drugstartperiod>259</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>136</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-04-21</drugenddate>
				<drugtreatmentduration>123</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="6">Not Applicable</actiondrug>
				<activesubstance>
					<activesubstancename>liraglutide</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Retinal vein occlusion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Unlikely</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Retinal vein occlusion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Trial ID: EX2211-3748Trial title: A Long term, Multi centre, International, Randomised Double <Semaphore x="2794786" class="MedDRA LLT" value="Blindness" score="1.00" ID="10005169">blind</Semaphore>, <Semaphore x="2404766" class="AnatomicStructure" value="Placenta" score="1.00" ID="C13272">Placebo <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore></Semaphore>Trial to Determine <Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">Liraglutide </Semaphore>Effects on <Semaphore x="1726192" class="AnatomicStructure" value="Cardiovascular System" score="1.00" ID="C12686">Cardiovascular </Semaphore>Events. LEADER<Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">Liraglutide </Semaphore>Effect and Action in <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">Diabetes</Semaphore>: <Semaphore x="2843904" class="MedDRA LLT" value="Cardiovascular evaluation" score="1.00" ID="10053046">Evaluation of <Semaphore x="1726192" class="AnatomicStructure" value="Cardiovascular System" score="1.00" ID="C12686">Cardiovascular </Semaphore></Semaphore><Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">Results</Semaphore>Phase: 3bInvestigational <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs</Semaphore>: <Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">Liraglutide </Semaphore>vs. PlaceboPatient ID: 912043Patient's <Semaphore x="1387854" class="Height" value="166 centimetres" score="1.00" ID="">height: <Semaphore x="5960787541622785" class="Height" value="166 centimetres" score="1.00" ID="">166 centimetres</Semaphore></Semaphore>This clinical trial case from the Unites States was reported as "<Semaphore x="1630798" class="AnatomicStructure" value="Branch" score="1.00" ID="C61482">branch </Semaphore><Semaphore x="2466052" class="Disease or Finding" value="Retinal Vein Occlusion" score="1.00" ID="C34981">retinal vein occlusion</Semaphore>" and <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a 66-year old male patient. The patient was treated with trial <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore><Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">Liraglutide </Semaphore>vs. Placebo from 20-DEC 2011 to 21-APR 2012 for <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type 2 diabetes mellitus</Semaphore>.Medical history includes <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985"><Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type 2 diabetes mellitus </Semaphore>since 1988, </Semaphore><Semaphore x="2917668" class="MedDRA LLT" value="Dyslipidaemia" score="1.00" ID="10058108">dyslipidaemia</Semaphore>, <Semaphore x="1965163" class="Disease or Finding" value="Gastroesophageal Reflux Disease" score="1.00" ID="C26781">gastroesophageal reflux disease</Semaphore>, nonproliferative <Semaphore x="2467690" class="Disease or Finding" value="Retinopathy" score="1.00" ID="C62601">retinopathy </Semaphore>since 2004, <Semaphore x="2306402" class="Disease or Finding" value="Neuropathy" score="1.00" ID="C4731">neuropathy peripheral</Semaphore><Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">, <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376"><Semaphore x="1781618" class="Disease or Finding" value="Chronic Renal Failure" score="1.00" ID="C9438">chronic <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">renal <Semaphore x="2102626" class="Disease or Finding" value="Left Ventricular Failure" score="1.00" ID="C50630">failure</Semaphore></Semaphore></Semaphore>
       <Semaphore x="3227517" class="MedDRA LLT" value="Renal infarct" score="1.00" ID="10038470">
        <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">
         <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
          </Semaphore></Semaphore>
        <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
         </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">
      <Semaphore x="3227517" class="MedDRA LLT" value="Renal infarct" score="1.00" ID="10038470">
       <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
        </Semaphore></Semaphore></Semaphore>
     <Semaphore x="3227517" class="MedDRA LLT" value="Renal infarct" score="1.00" ID="10038470">
      <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
       <Semaphore x="2102626" class="Disease or Finding" value="Left Ventricular Failure" score="1.00" ID="C50630">, </Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3227517" class="MedDRA LLT" value="Renal infarct" score="1.00" ID="10038470">
     <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
      <Semaphore x="2253052" class="Disease or Finding" value="Myocardial Infarction by ECG Finding" score="1.00" ID="C101589">myocardial infarction</Semaphore></Semaphore></Semaphore>
    <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
     <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">, <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore><Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">, left <Semaphore x="3311584" class="MedDRA LLT" value="Ventricular hypertrophy" score="1.00" ID="10047295">ventricular </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
      <Semaphore x="2102702" class="Disease or Finding" value="Left Ventricular Hypertrophy" score="1.00" ID="C50631">
       </Semaphore>
      <Semaphore x="2038611" class="Disease or Finding" value="Hypertrophy" score="1.00" ID="C3124">hypertrophy </Semaphore></Semaphore></Semaphore>and <Semaphore x="2370735" class="Disease or Finding" value="Pancreatitis" score="1.00" ID="C3306">pancreatitis</Semaphore>. The patient is a former <Semaphore x="3280826" class="MedDRA LLT" value="Tobacco user" score="1.00" ID="10057581">smoker</Semaphore>.On 04-SEP 2012 the patient went to the general optometry for a comprehensive exam. Exam findings showed new <Semaphore x="1630798" class="AnatomicStructure" value="Branch" score="1.00" ID="C61482">branch </Semaphore><Semaphore x="2466052" class="Disease or Finding" value="Retinal Vein Occlusion" score="1.00" ID="C34981">retinal vein occlusion </Semaphore>in the right <Semaphore x="1916070" class="AnatomicStructure" value="Eye Segment" score="1.00" ID="C33525">eye</Semaphore>. The patient had a follow up exam and the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">doctor </Semaphore>felt that the <Semaphore x="2466052" class="Disease or Finding" value="Retinal Vein Occlusion" score="1.00" ID="C34981">retinal vein occlusion </Semaphore>was mostly a systemic manifestation of <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension </Semaphore>(<Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">HTN</Semaphore>), HLD and <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus </Semaphore>(<Semaphore x="1863607" class="Disease or Finding" value="Double Outlet Right Ventricle" score="1.00" ID="C98916">DM</Semaphore>). According to the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">doctor</Semaphore>, <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="1.00" ID="C12814">vein </Semaphore><Semaphore x="1841229" class="Disease or Finding" value="Dental Occlusion" score="1.00" ID="C62301">occlusion </Semaphore>when it comes to the retinal <Semaphore x="1607047" class="Disease or Finding" value="Blood Clot" score="1.00" ID="C27083">circulation </Semaphore>is more common due to anatomic reasons and also considered to represent a frequent <Semaphore x="1883294" class="Procedure" value="End-of-Life Treatment Management" score="1.00" ID="C67359">end </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">result </Semaphore>of <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">HTN</Semaphore>. No concomitant medications associated.<Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>of the event has not been reported.Action taken to trial <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>is reported as not applicable.Investigator's causality:<Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">Liraglutide </Semaphore>vs. Placebo: probableSponsor's causality:<Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">Liraglutide </Semaphore>vs. Placebo: unlikelyOn 23-JAN 2013 trial <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>was un <Semaphore x="2794786" class="MedDRA LLT" value="Blindness" score="1.00" ID="10005169">blinded </Semaphore>according to regulatory requirements. Information on actual <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>can be <Semaphore x="2328864" class="Disease or Finding" value="Obtundation" score="1.00" ID="C28209">obtained </Semaphore>from Global Safety for regulatory purposes.On 25-JAN 2013 a correction was performed within regulatory timelines, Investigator's causality assesment in the narrtive was changed from possible to probableComment: company comment:<Semaphore x="1606559" class="Disease or Finding" value="Blockage" score="1.00" ID="C50468">Blockage </Semaphore>of smaller <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="1.00" ID="C12814">veins </Semaphore>(<Semaphore x="1630798" class="AnatomicStructure" value="Branch" score="1.00" ID="C61482">branch </Semaphore><Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="1.00" ID="C12814">veins</Semaphore>) in the <Semaphore x="1130515" class="Medicine" value="Retin-A" score="0.49" ID="239679">retina </Semaphore>often occurs when <Semaphore x="2465496" class="AnatomicStructure" value="Retinal Artery" score="1.00" ID="C52997">retinal arteries </Semaphore>that have been thickened or hardened by <Semaphore x="1552673" class="Disease or Finding" value="Atherosclerosis" score="1.00" ID="C35768">atherosclerosis </Semaphore>and which cross over a <Semaphore x="2466070" class="AnatomicStructure" value="Retinal Vein" score="1.00" ID="C53063">retinal vein</Semaphore>, can compress the <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="1.00" ID="C12814">vein </Semaphore>and <Semaphore x="2811880" class="MedDRA LLT" value="Blood lead" score="1.00" ID="10005639">lead </Semaphore>to changes in the flow and to thrombus formation. <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">Hypertensive</Semaphore>, atherosclerotic, inflammatory, or thrombophilic conditions may <Semaphore x="2811880" class="MedDRA LLT" value="Blood lead" score="1.00" ID="10005639">lead </Semaphore>to <Semaphore x="2465570" class="Disease or Finding" value="Retinal Damage" score="1.00" ID="C50731">retinal <Semaphore x="1888158" class="AnatomicStructure" value="Endothelium" score="1.00" ID="C12481">endothelial </Semaphore>vascular damage</Semaphore>. (1) This patient has multiple risk factors for <Semaphore x="1552673" class="Disease or Finding" value="Atherosclerosis" score="1.00" ID="C35768">atherosclerosis </Semaphore>(<Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>, <Semaphore x="2917668" class="MedDRA LLT" value="Dyslipidaemia" score="1.00" ID="10058108">dyslipidaemia</Semaphore>, <Semaphore x="2253052" class="Disease or Finding" value="Myocardial Infarction by ECG Finding" score="1.00" ID="C101589">myocardial infarction </Semaphore>and <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type 2 <Semaphore x="2904422" class="MedDRA LLT" value="Diabetes mellitus" score="1.00" ID="10012601">diabetes</Semaphore></Semaphore>). The <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>was <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">made </Semaphore>at an examination over four months after discontinuation of trial product, <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">making </Semaphore>date of onset of the event unclear. However, since GLP 1 analogues such as <Semaphore x="793195" class="Medicine" value="liraglutide" score="0.99" ID="269156">liraglutide </Semaphore>have shown a <Semaphore x="2308198" class="Disease or Finding" value="Neutral Epithelial Mucin Present" score="1.00" ID="C43907">neutral </Semaphore>or favourable effect on many of these risk factors including <Semaphore x="3016136" class="MedDRA LLT" value="Hyperglycaemia" score="1.00" ID="10020635">hyperglycaemia</Semaphore>, <Semaphore x="2059929" class="Disease or Finding" value="Insulin Resistance" score="1.00" ID="C113101"><Semaphore x="733661" class="Medicine" value="Insulin" score="0.49" ID="275827">insulin </Semaphore>resistance</Semaphore>, <Semaphore x="2917668" class="MedDRA LLT" value="Dyslipidaemia" score="1.00" ID="10058108">dyslipidaemia</Semaphore>, and <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>, they may be expected to have a <Semaphore x="2308198" class="Disease or Finding" value="Neutral Epithelial Mucin Present" score="1.00" ID="C43907">neutral </Semaphore>or favourable effect on vascular events.1. Wu L. <Semaphore x="1630798" class="AnatomicStructure" value="Branch" score="1.00" ID="C61482">Branch </Semaphore><Semaphore x="2466052" class="Disease or Finding" value="Retinal Vein Occlusion" score="1.00" ID="C34981">Retinal Vein Occlusion</Semaphore>. http://emedicine.medscape.com/article/1223498-overview. 20-AUG 2012.</narrativeincludeclinical>
				<reportercomment>Investigator's alternative aetiology: Unknown</reportercomment>
				<sendercomment>Blockage of smaller veins (branch veins) in the retina often occurs when retinal arteries that have been thickened or hardened by atherosclerosis and which cross over a retinal vein, can compress the vein and lead to changes in the flow and to thrombus formation. Hypertensive, atherosclerotic, inflammatory, or thrombophilic conditions may lead to retinal endothelial vascular damage. (1) This patient has multiple risk factors for atherosclerosis (hypertension, dyslipidaemia, myocardial infarction and type 2 diabetes). The diagnosis was made at an examination over four months after discontinuation of trial product, making date of onset of the event unclear. However, since GLP-1 analogues such as liraglutide have shown a neutral or favourable effect on many of these risk factors including hyperglycaemia, insulin resistance, dyslipidaemia, and hypertension, they may be expected to have a neutral or favourable effect on vascular events.

1. Wu L. Branch Retinal Vein Occlusion. http://emedicine.medscape.com/article/1223498-overview. 20-AUG-2012.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>